Abstract
A series of novel 5-fluorine-benzimidazole-4-carboxamide analogs were designed and synthesized. All target compounds were evaluated for their PARP-1 inhibitory activity. Compounds possessed high intrinsic PARP-1 inhibitory potency have been evaluated in vitro cellular assays to measure the potentiation effect of cytotoxic agents against cancer cell line. These efforts led to the identification of compound 10f, which displayed strong inhibition against the PARP-1 enzyme with an IC50 of 43.7nM, excellent cell inhibitory activity in HCT116 cells (IC50=7.4μM) and potentiation of temozolomide cytotoxicity in cancer cell line A549 (PF50=1.6).
Keywords:
Antitumor; Benzimidazole; Fluorine atom; Inhibitors; PARP-1.
Copyright © 2016 Elsevier Ltd. All rights reserved.
MeSH terms
-
A549 Cells
-
Amides / chemical synthesis
-
Amides / chemistry*
-
Amides / toxicity
-
Antineoplastic Agents / chemical synthesis*
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / toxicity
-
Benzimidazoles / chemical synthesis*
-
Benzimidazoles / chemistry*
-
Benzimidazoles / toxicity
-
Binding Sites
-
Cell Survival / drug effects
-
Dacarbazine / analogs & derivatives
-
Dacarbazine / toxicity
-
Drug Design*
-
Enzyme Inhibitors / chemical synthesis*
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / toxicity
-
HCT116 Cells
-
Humans
-
Molecular Docking Simulation
-
Poly (ADP-Ribose) Polymerase-1 / antagonists & inhibitors*
-
Poly (ADP-Ribose) Polymerase-1 / metabolism
-
Protein Binding
-
Protein Structure, Tertiary
-
Structure-Activity Relationship
-
Temozolomide
Substances
-
5-fluoro-1H-benzimidazole-4-carboxamide
-
Amides
-
Antineoplastic Agents
-
Benzimidazoles
-
Enzyme Inhibitors
-
Dacarbazine
-
benzimidazole
-
Poly (ADP-Ribose) Polymerase-1
-
Temozolomide